We are a UK biotech company focused on discovering and developing a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of the enzymes, N-myristoyltransferases (NMT) for the treatment of cancer.
At Myricx we are advancing a proprietary pipeline of new generation ADCs to address significant unmet needs in oncology. Our ADCs have demonstrated excellent preclinical efficacy and safety across multiple solid tumour associated antigens and cancer cell types.
Led by a team of drug hunters and internationally renowned scientists with small molecule and ADC drug development experience and outstanding track records of commercial and academic successes.
- Myricx Expands its Leadership Team with the Appointment of Dr. Robert McLeod as VP Clinical Development 13 September 2023 - Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective…
- Myricx Enters into Antibody License Agreement with Biocytogen 7 September 2023 - Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective…